Ssu-Ju Li1, Hui-Yu Wang1, Hui-Ching Lin2,3, Ting-Chun Lin1, Han-Fang Wu2, Chi-Wei Lee2, Yu-Chun Lo4, You-Yin Chen1, and Hsin-Yi Lai5
1Department of Biomedical Engineering, National Yang-Ming University, Taipei, Taiwan, 2Department and Institute of Physiology, National Yang-Ming University, Taipei, Taiwan, 3Brain Research Center, National Yang-Ming University, Taipei, Taiwan, 4The PhD Program for Neural Regenerative Medicine, Taipei Medical University, Taipei, Taiwan, 5Interdisciplinary Institute of Neuroscience and Technology, Zhejiang University, Hangzhou City, Zhejiang Province, People's Republic of China
Synopsis
This study demonstrates changes of functional connectivity in motor
related brain areas and the motor cortex and striatum may be crucial areas for
treatment and evolution of autism
spectrum disorder (ASD). Our results indicate
that both CT-DBS and 5-TH
treatments can alter the social interaction and motor related functional connectivity VPA-induced ASD rats by modifying the motor
cortico-striatal circuit. The rsfMRI has the potential to explore functional
connectivity in the brain and monitor functional plasticity changes in a
specific neuroanatomical pathway in vivo.
INTRODUCTION
Autism
spectrum disorder (ASD) is a lifelong neurodevelopmental disorder characterized by
weak social interaction, communication, stereotyped and repetitive
behaviors1. Valproic
acid (VPA) can alter
mood stability by modifying
gamma-aminobutyric acid (GABA) levels2,3 and increase the risk of ASD4. The VPA-induced ASD model can produce genetic and behavioral phenotype with similar clinical significance of ASD5.
A previous study indicated that VPA can inhibit connectivity of motor circuits
in primary motor (M1) → pre-motor cortex (PMd) and M1 → supplementary area
motor (SMA)6. Therefore, our hypothesis is that modulating the motor
circuits may
improve the social and cognitive
deficits in ASD. Deep brain stimulation in the central thalamus (CT-DBS) has been demonstrated that can increase the
exploratory motor behaviors and enhance cognitive performance and skill learning by increasing the cortico-striatal connectivity7,8.
In addition, 5-hydroxytryptamine (5-HT) has been considered a neurochemical
biomarker of ASD9. The
8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), which is a 5-HT1A receptor agonist, can increase
social interaction in the VPA-induced ASD by promoting combination with 5-HT and 5-HT1A receptor10. In this study, we
proposed that use of CT-DBS or 8-OH-DPAT therapies treat the VPA-induced ASD
rats. Then, we
used resting-state functional MRI (rsfMRI) to evaluate the changes of functional connectivity at
cortico-cortical and cortico-striatal pathway for effectiveness comparison of CT-DBS and 8-OH-DPAT.METHODS
Adult
female Sprage Dawley rats (weight 250-300 g) were housed in the animal facility under 12:12-h light/dark cycle
(lights on at 7:00 am) with
controlling temperature at 22 ± 2°C and then the rats
were mated. The pregnant rats in
VPA group were received a single intraperitoneal injection of VPA (500 mg/Kg) at the pregnancy day of
12-1311 and
the rats in control group were injected with saline. The offspring were evaluated by a standard social interaction
behavioral testing. Twenty offspring were used in this study, including the
control (n=5), VPA-induced ASD (n=5),
CT-DBS
(n=5) and 8-OH-DPAT (n=5) groups. The social testing included three
chambered facility including empty, central, and social, and how long the rats
spent in each facility were calculated (Fig.
1A). In the CT-DBS group, MRI-compatible 16-channel neural probes (Fig. 1B) were stereotactically
implanted into central lateral thalamus (AP: -2.5 mm, ML: ±1.4 mm, and DV: 4.5
mm) in the VPA-induced ASD rats. Then the DBS was implemented with
a bipolar square-wave current of 0.4 mA with 25 μs pulse-width at 100 Hz for 30
min, once a day for three
days. In the 8-OH-DPAT group, 8-OH-DPAT
dissolving in 0.9% normal saline was injected (0.5 mg/d.kg body weight)
intraperitoneally daily into the VPA-induced rats for 7 days. For fMRI experiments, rats
were anesthetized with 0.1 mg/kg Dexdomitor® subcutaneously. MRI was performed
on a Bruker Biospec 7T system with a 30-cm diameter bore and a single-shot
GE-EPI sequence (TR/TE=2000/20 ms, BW=200 kHz, 80×80 matrix, FOV=25×25 mm2,
thickness=1 mm, slice number = 10) was used to acquire rsfMRI images totaling 260
scanning images for 10 dummy scanning and 250 images. Functional connectivity
were calculated by using Resting State fMRI Data Analysis Toolkit (REST)
v1.7 with seed-based method within a
2 x 2 pixel region of interest (ROI) in left and right primary motor (M1L
and M1R) and in left and
right striatum (StrL and StrR). Pattern
comparison of functional connectivity was computed by one sample t-test and
alphasim correction and the variables of functional connectivity were assessed
by Student’s t-test. The significant difference between groups was considered
if p value < 0.05. RESULTS & DISCUSSION
The social interaction
behavioral testing involving an
unfamiliar rat chamber (social chamber) and empty region and performed using
control-offspring, VPA-exposed offspring, VPA-exposed treatment with CT-DBS and
VPA-exposed treatment with 8-OH-DPAT. The results revealed that the VPA-exposed offspring spent slightly
less time with unfamiliar rat (social chamber) and more time in empty chamber
than did the control group. Both CT-DBS and 8-OH-DPAT treatments could improve the social
deficits in rats (Fig 2A).
Functional connectivity among the right hemispheric motor (M1R),
left hemispheric motor (M1L), right hemispheric striatum (StrR)
and left hemispheric striatum (StrL) were analyzed by rsfMRI. The
connectivity between M1L–M1R, M1L–StrL
and M1R–StrR was decreased in VPA-induced ASD group. The
effectives treatment of CT-DBS and 8-OH-DPAT could improve the functional connectivity of M1L–StrL
and M1R–StrR in VPA-induced ASD rats. Our results
suggested that both CT-DBS and 5-TH treatments were increased in the social interaction and functional connectivity
in the bilaterally intrahemispheric M1-striatum circuits in the VPA-induced
offspring. This study indicates cortico-striatal pathway play a potential therapy
role in ASD. Acknowledgements
This research is
financially supported by the Ministry Science and Technology of the Republic of
China, Taiwan under Contract numbers of MOST 103-2320-B-010-014-MY2, 103-2321-B-010-016
and 102-2221-E-010-001-MY3 and the Zhenjiang University, China under the Fund
number of 181110-193544B01/007.References
1. Loucas, T., Autism spectrum disorder. Supporting young children with
communication problems,
2015:104.
2. Jeremy J. at al., Lamotrigine–valproic acid combination therapy for medically
refractory epilepsy, Epilepsia, 2009, 50(3):475-479.
3. Rogawski, M. A. at al.,
The neurobiology of antiepileptic drugs, Nature Rev Neurosci, 2004, 5(7):
553-564.
4. Bromley, R. L., et al. Autism
spectrum disorders following in utero exposure to antiepileptic drugs. Neurol, 2008, 71(23):1923-1924.
5. Rinaldi, T. et al., Hyperconnectivity of local neocortical microcircuitry
induced by prenatal exposure to valproic acid. Cereb Cortex, 2008, 18(4):763-770.
6. Li, Xingbao, et al., Using interleaved transcranial magnetic
stimulation/functional magnetic resonance imaging (fMRI) and dynamic causal
modeling to understand the discrete circuit specific changes of medications:
lamotrigine and valproic acid changes in motor or prefrontal effective
connectivity. Psychiatry Research: Neuroimaging, 2011, 194(2):141-148.
7. Shirvalkar P. et al., Cognitive
enhancement with central thalamic electrical stimulation, PNAS, 2006, 103:17007-17012
8. Lin, Hui-Ching, et al. Central thalamic
deep-brain stimulation alters striatal-thalamic connectivity in cognitive
neural behavior, Front neural circuits, 2016, 9 (87):1-12.
9.
Hammock, Elizabeth, et al., Examining autism spectrum disorders by biomarkers:
example from the oxytocin and serotonin systems, JAACAP, 2012, 51.(7):
712-721.
10.Wang
C. C. et al., 5-HT1A-receptor agonist modified amygdala activity and
amygdala-associated social behavior in a valproate-induced rat autism model.
Int J Neuropsycho-pharmacol, 2013, 9:2027-2039.
11. Markram, K.,
et al. Abnormal fear conditioning and amygdala processing in an animal model of
autism, Neuropsychopharmacol, 2008, 33(4):
901-912.